Testing two medications together for a rare blood and immune disorder

Plain-English translation of NCT07270835 on ClinicalTrials.gov ↗ · Source last updated December 2025 · Translation generated July 2026 · How we translate trials

Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.

What is this trial?

This trial is testing whether combining with —along with a few other supportive medications—can help treat a rare condition called hemophagocytic lymphohistiocytosis (HLH) that develops in patients with B-cell lymphoma. HLH occurs when the immune system becomes overactive and starts attacking the body's own cells. The study will see if this medication combination can control both conditions at the same time.

HLH is a life-threatening condition where the immune system goes into overdrive, and it's especially dangerous when it happens alongside blood cancer. Doctors need better treatment options for patients facing both conditions, and this medication combination shows promise in early results.

Do you qualify?

You likely qualify if…

you have been diagnosed with hemophagocytic lymphohistiocytosis (HLH) and B-cell lymphoma, or have signs of B-cell lymphoma in your bone marrow
you are between 14 and 80 years old
you are expected to live for at least one more month
your heart, liver, and kidney function are stable enough for this treatment
you do not have serious uncontrolled infections like pneumonia, intestinal infections, or sepsis
you are willing to use effective birth control during the study and for at least 3 to 12 months after treatment ends

You likely don't qualify if…

you have a severe allergy to rituximab, zanubrutinib, or similar medications
you currently have severe infections (bacterial, viral, or fungal) that cannot be controlled
you have serious heart, liver, or kidney disease that makes treatment unsafe
you are pregnant, breastfeeding, or unwilling to use birth control
you are currently taking other experimental drugs and have not finished a required waiting period

What participation looks like

You will receive intravenously once a week for 4 weeks, and take as a pill twice daily for the same 4 weeks. You will also take prednisone, ruxolitinib, and possibly another medication called emapalumab, depending on your needs. Your doctor will adjust doses based on how well you tolerate the treatment and how your condition responds. You'll have regular visits to monitor your blood counts, organ function, and overall health throughout the study.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Trial locations(1 site)

China

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu